Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 3, 2012, Pages 373-378

  Na, Im Il ^a   Kim, Hye Ryoun ^a   Lee, Jin Kyung ^a   Park, Sun Hoo ^a   Kim, Cheol Hyeon ^a   Koh, Jae Soo ^a   Baek, Hee Jong ^a   Choe, Du Hwan ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Epidermal growth factor receptor female; Mutation; Non small cell lung cancer; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS RESECTION; PHYSICAL EXAMINATION; PLEURA METASTASIS; POSTOPERATIVE PERIOD; RECURRENT CANCER; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84873402328     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.103515     Document Type: Article

References (40)

1. Lee CT. Epidemiology of Lung Cancer in Korea. Cancer Res Treat 2002;34:3-7.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Immerman SC, Vanecko RM, Fry WA, Head LR, Shields TW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981;32:23-7.
4. Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
5. Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y, et al. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 2001;7:204-9.
6. Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol 2009;4:518-21.
7. Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: Emerging differences in epidemiology, biology, and therapy. Chest 2005;128:370-81.
8. Chun BY, Yang JH, Song JH, Lim JS. Annual average cancer incidence and trend of cancer incidence in Daegu for 5 years, 1997~2001. Korean J Epidemiol 2007;29:59-69.
9. Patel JD. Lung cancer in women. J Clin Oncol 2005;23:3212-8.
10. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13:1087-93.
11. Minami H, Yoshimura M, Miyamoto Y, Matsuoka H, Tsubota N. Lung cancer in women: Sex-Associated differences in survival of patients undergoing resection for lung cancer. Chest 2000;118:1603-9.
12. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
13. Ko YC, Lee CH, Chen MJ, Huang CC, Chang WY, Lin HJ, et al. Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997;26:24-31.
14. Shimizu H, Tominaga S, Nishimura M, Urata A. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. Jpn J Clin Oncol 1984;14:595-600.
15. Koo LC, Ho JH. Worldwide epidemiological patterns of lung cancer in nonsmokers. Int J Epidemiol 1990;19 Suppl 1:S14-23.
16. Na II, Choe du H, Kim CH, Koh JS, Ryoo BY, Lee JC, et al. Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer. Lung Cancer 2010;68:295-8.
17. Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH, et al. Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J Thorac Oncol 2010;5:1949-52.
18. Sekine I, Yamamoto N, Nishio K, Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-62.
19. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
20. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
21. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
22. Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, et al. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: An extension of the ovarian BRCAness phenotype. J Clin Oncol 2010;28:2505-11.
23. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-8.
24. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
25. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, et al. Epidermal growth factor receptor mutations as a prognostic factor in Korean patients with advanced lung adenocarcinoma who had not been treated with received epidermal growth factor receptor tyrosine kinase inhibitors. Chemotherapy 2011;57:108-14.
26. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975;70:606-12.
27. Na II, Kang HJ, Cho SY, Koh JS, Lee JK, Lee BC, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007;43:520-6.
28. Na II, Park JH, Choe DH, Lee JK, Koh JS. Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentation in Non-small Cell Lung Cancer. ISRN Oncol 2011;2011:756265.
29. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;44:793-7.
30. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004;64:8919-23.
31. Hotta K, Kiura K, Takigawa N, Kuyama S, Segawa Y, Yonei T, et al. Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol 2009;135:117-23.
32. Yamazaki K, Sugio K, Yamanaka T, Hirai F, Osoegawa A, Tagawa T, et al. Prognostic factors in non-small cell lung cancer patients with postoperative recurrence following third-generation chemotherapy. Anticancer Res 2010;30:1311-5.
33. Boyd JA, Hubbs JL, Kim DW, Hollis D, Marks LB, Kelsey CR. Timing of local and distant failure in resected lung cancer: Implications for reported rates of local failure. J Thorac Oncol 2010;5:211-4.
34. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26:5589-95.
35. Katayama T, Matsuo K, Kosaka T, Sueda T, Yatabe Y, Mitsudomi T. Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study. Surg Oncol 2010;19:e144-9.
36. Dunant A, Pignon JP, Le Chevalier T. Adjuvant chemotherapy for non-small cell lung cancer: Contribution of the International Adjuvant Lung Trial. Clin Cancer Res 2005;11:5017s-21s.
37. Park JH, Lee CT, Lee HW, Baek HJ, Zo JI, Shim YM. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2005;27:1086-91.
38. Park JH, Shim YM, Baek HJ, Kim MS, Choe DH, Cho KJ, et al. Postoperative adjuvant therapy for stage II non-small-cell lung cancer. Ann Thorac Surg 1999;68:1821-6.
39. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-22;discussion 22-3.
40. Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D'Amico TA, et al. Local recurrence after surgery for early stage lung cancer: An 11-year experience with 975 patients. Cancer 2009;115:5218-27.